CYPH (Cypherpunk Technologies) Short Interest


CYPH Cypherpunk Technologies Inc CYPH
28 GF Score
Price $0.63
! 3 Warning Signs
View Full Analysis

What is Cypherpunk Technologies Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

CYPH vs PFO, NMI, GGZ: Short Interest Comparison

For the Asset Management subindustry, Cypherpunk Technologies's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cypherpunk Technologies Short Interest vs Asset Management Industry

For the Asset Management industry and Financial Services sector, Cypherpunk Technologies's Short Interest distribution charts can be found below:

* The bar in red indicates where Cypherpunk Technologies's Short Interest falls into.


CYPH
28GF Score
Cypherpunk Technologies Inc CYPH
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cypherpunk Technologies Business Description

Other Exchanges 5MC:Germany
Address 47 Thorndike Street, Suite B1-1, Cambridge, MA, USA, 02141
Cypherpunk Technologies Inc is a privacy technology company focused on implementing a digital asset treasury business anchored by Zcash, which is a cryptographic digital asset that operates on a decentralized, open-source blockchain network known as the Zcash Network. Through its subsidiary, the company is also engaged in developing novel therapies for patients with cancer. The group holds Zcash as part of its digital treasury business and has the following drug candidates under development in its biopharma business: Sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1; and a preclinical antibody program, FL-501, that is designed to treat cachexia-related indications.
28GF Score

Get the complete analysis for CYPH

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.63
Price